Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET): later-stage trial registry
1 of 1 indexed Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #11,370 of 28,707 conditions by registered trial count.
1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count
Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET): 1 US clinical trial tracked, 1 recruiting.
Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Novartis Pharmaceuticals, running 1 of these trials.
Enrollment posture brief
Registry condition gastroenteropancreatic-neuroendocrine-tumor-gep-net
OPEN 1 | RECR 100% | LATE 1 | EARLY 0 | RANK #11370 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) is recruiting above its size-band peers.
1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
1 total, page 1 of 1
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) page
1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Novartis Pharmaceuticals sponsors the most Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) trials on record, review their full trial history before evaluating a specific study. See Novartis Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) condition card totals 1 registered trials; most-linked intervention Octreotide LAR; top US site state Virginia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.